POWERED BY

Building Cardiolyse – the distance from a good algorithm to a doctor’s desk

PublishedNovember 16, 2026

Normunds Daudiss is the CEO of Cardiolyse, a Helsinki-based company developing a CE-certified, AI-powered ECG analytics platform. Originally from Latvia, he runs the company from Finland, drawn by its growth potential and advanced data infrastructure. He has always considered himself sector-agnostic.

Ahead of the MEDICA trade fair in Düsseldorf, NXTin.Health speaks with Normunds about the latest version of their product, the perennial “Europe or USA?” debate, AI as an everyday part of business, and what it takes to build a medtech company across 27 different European markets.

You have said that artificial intelligence should help healthcare professionals make better decisions rather than replace their judgement. In your view, are we overestimating what AI can do in healthcare right now, or are we only beginning to understand its real potential?

We are definitely not overestimating it. If anything, the hype phase is already a little behind us, and we have moved to the next step: working out how to use these solutions in practice.

I was recently in Germany for the European Society of Cardiology Congress, the major annual meeting for cardiologists. A year ago, everyone was asking how AI could help across different areas of heart health. This year, that question had largely disappeared. AI is now widely accepted in cardiology, and the discussion has shifted to how to use it effectively. What regulation do we need? What systematic, evidence-based outcomes do we need to make better use of it? Whether AI can help doctors is no longer the main question. The question is how to integrate it safely into everyday clinical practice and use it at scale.

Where is health innovation heading at the moment? Is the main focus on extending life, improving quality of life or preventing disease, or is the sector already moving towards something we cannot quite see yet?

AI now reaches into practically every area, including some that today’s healthcare systems barely address. Early diagnostics is one such area, and longevity, which has become very fashionable, is another.

For us, early diagnostics matters a great deal, especially in primary care. We focus on heart data. By detecting even the smallest changes in an electrocardiogram, we can identify certain cardiac irregularities and flag risk indicators that may require closer follow-up.

My own daily focus is fairly narrow because we work only with ECG data. However, our partners, who use our data in their own analyses, and large players in the field are combining as many incoming data streams as possible – from every kind of sensor across the body – to identify correlations across a much broader picture. We are a small niche within that larger trend.

As a medical-grade technology, our analysis is used at different stages of the patient journey. We help healthcare professionals diagnose heart health status and risks in general population early at an early stage. We also help healthcare facilities manage the growing burden of ECG data analysis and facilitate remote cardiac assessments after patients return home.

Preventive screening and longevity, I would say, are still closer to the hype stage. From what I have seen, healthcare funding is not really flowing into these areas at present. So we need to use grant funding and R&D budgets to demonstrate that the value is there.

So, the commercial opportunities are still missing there?

For risk scoring and preventive assessments, yes. Our main offering focuses on medically recognised arrhythmias and cardiac diagnoses that our AI-powered algorithms help detect and identify. At the same time, from the early days, we have also offered analytics that support our wellness offering, covering heart rate variability, stress, stamina, heart health age and similar parameters.

That area is very interesting, and more and more smart consumer devices are analysing these data in greater depth. Although patients may be interested in these metrics, in most commercial cases our clients generally are not. We are asked not to display these additional parameters, but to focus only on what is clinically recognised and qualifies as medical-grade technology. We are asked to leave out anything novel or any additional risk indicators because they have no mechanism of using them in daily practice.

Why is that? Is it because the data cannot be trusted enough?

A large share of this data does not come from medical sensors, nor is it processed using approved medical technology or medical algorithms. So it remains wellness data. It can indicate trends in a user’s state of health, but that is where its usefulness stops.

Another important factor is medical training and clinical evidence. Doctors are trained to work with a defined set of clinical inputs, and new parameters need solid evidence before they can be incorporated into daily practice. That is changing as new publications, studies and correlations emerge, but it takes time. We may read about healthtech innovation every day, but adoption in hospitals is slower, and for good reason: patient safety comes first.

Let’s talk about you. What is your background, and how did you end up in Finland? Why Finland?

I am a businessperson. I studied business and finance and have worked in that field, but I have always considered myself sector-agnostic. I like innovation and things that bring change and improve the systems and the world around us. I have worked in finance, hospitality and biotechnology.

As for healthcare, my story is probably similar to that of many other founders. There were cases in my family where heart health technology could have helped someone live longer by identifying a heart problem earlier. About 10 years ago, I came across a company that had this kind of innovative technology. I became an early business angel investor, despite having no experience or understanding of healthcare or cardiology. I was driven by the big goal that this this technology could have.

The company was established in Finland, which was considered the best place for health innovation at the time. I still think that was the right decision. Finland’s digital openness and access to the right stakeholders are comparatively strong. Coming from Latvia myself, I can see that digital readiness and access to data there are much more limited. Business Finland also offered strong early-stage support through grants and various projects.

So I came to healthcare headfirst, driven by the desire to build something meaningful and change the world: to bring this heart health solution to people, detect problems earlier and help people live longer.

Business visionaries who want to bring about change usually have to rely heavily on their teams, particularly people who can deliver the technical and scientific work. Where did you find a team you could trust?

The team is essential. I should say that it was only two years ago that I took over the management of the company I had first invested in. Like many young companies, we had reached the point where we needed a sharper focus: choosing a specific niche, creating clear value in it, and validating with buyers that they are willing to pay for it. With the support of our shareholders, I took on the role of CEO to rebuild the company around that focus and carry our joint vision forward.

On the technology side, the team was crucial because everything rests on our algorithms. The moment I took over also happened to coincide with a breakthrough in AI, particularly in programming and algorithm development. That allowed us to optimise how the company works and become more efficient. Today, with a team of just under 10 people, a great deal of what we achieve is supported by AI tools across every area: marketing, market research, sales support and technology validation. Of course, wherever we work with medical technology, we use AI in line with MDR requirements, and we are preparing for the EU AI Act. We have great specialists in tech development, as well as clinical and medical advisers who keep us aligned and allow us develop a product that users genuinely need.

What stage is your product at now?

Our CE-certified product has been on the market for years. However, since the new management took over, we have completely rebuilt and improved it. Just a couple of weeks ago, we launched the latest version of our fully redesigned ECG Workspace. It includes AI-powered algorithms and brings automated analysis and clinician-led review of 12-lead resting ECGs into one environment.

Our team will be at MEDICA in Germany, the largest trade fair of its kind, where we will present the product to customers. We also have further innovations coming to market soon that respond closely to current demand. One is Holter ECG data analytics; the other is paper ECG digitisation, which allows users to convert paper electrocardiograms into digital data and analyse them properly.

How do you see Finland’s potential in health innovation compared with Latvia? Perhaps the two are hard to compare, but since your business is run from Finland, can you tell us more about that market?

It is hard to compare the two, because it all comes down to digital openness, systems and access to data. With the European Health Data Space regulation now coming into force, Finland is seen as a pioneer that other countries are already learning from, because it had put many of these elements in place before such a plan even existed.

The reason I keep coming back to data is that one of the most important things for an AI-powered start-up that wants to test and validate its solution early is access to suitable datasets and the ability to integrate with a potential partner. That partner’s infrastructure must be ready to allow a start-up to work with it in a secure environment. In Latvia, both access to data and test beds, as well as integration options, remain very limited and are largely still at the planning stage.

So in that respect, Nordic countries are more advanced. At the moment, we are hoping to establish exactly this kind of collaboration with a leading Nordic university hospital in Sweden. They have dedicated teams working on innovation and digital health technologies to help start-ups grow and develop – or fail fast and pivot.

Then there are local incubators and the readiness of the ecosystem. When we started, there was almost nothing in Latvia. Now I am a member of the Latvian Digital Health Association, where there is real activity, and the Latvian American Chamber of Commerce (AmCham) also has strong working groups in digital healthcare. In Finland, the whole ecosystem – with incubators, accelerators, health stakeholders and investors – had already been in place for many years.

What is interesting now is that, much like choosing which country to open a bank account in, companies can choose where to innovate. We see several Finnish companies setting up subsidiaries in Estonia because Estonia’s innovation system and support mechanisms are very open to Finnish start-ups that create added value in Estonia. That is competition between countries: attracting innovation so that it can be developed locally.

That is an interesting angle on competition. Looking further ahead, where do you see more opportunities to develop your product and services – in Europe or in the United States?

That has been a long-running discussion. We chose the European route, perhaps because it seemed easier and because the CE-marking process was more familiar to us. Perhaps the cost of starting something in the US also put us off at the time.         

What we see now is that, even with a common EU framework for CE marking, every European country still has its own local systems for reimbursement, public funding and compensation schemes, as well as different levels of openness to innovation, doctors’ willingness to adopt it, and access to data. As a result, healthtech companies have to enter markets country by country. Fortunately, in our case, we work mostly through partners who handle market entry for us.

If you are ready to take the step into the US market, the system there is organised at the national level. Once you have proper validation, FDA clearance and reimbursement codes, you can focus mainly on selling and scaling.

With our new products, our main focus for now is the European market. We also receive enquiries from Asia and the Middle East, and I would say that next year the US could become one of our target markets. Heart health problems remain pressing in every country, and the pressure on health systems will only grow.

We have touched on the problem that the European Union is not one market but 27 different ones. Every market has its own processes and reimbursement challenges. We hear this from almost every medtech company. Since healthcare remains a national competence, it cannot be regulated quickly, and many companies look to the US instead. Among the companies we have surveyed, 80% follow the “innovate in Europe, commercialise in the US” model. Do you expect this to change?

I don’t expect that pattern to change quickly, and I understand why it exists. In the US, once you have FDA clearance and reimbursement codes, you have access to one large market. In Europe, you still have to enter markets country by country. For us, Europe remains our base and our focus with the new products, because that is where we have our CE mark, clinical partners and validation. But with strong European evidence behind us, finding the right partners and taking our solution to the US is the logical next step.

Finally, how do you see yourself – as a Latvian innovator or a Finnish one? And does Latvia regard you as one of its success stories?

Actually, I have always wanted to include Latvia’s success story in some way as well. As a shareholder and CEO, I naturally represent and drive Finnish innovation forward. At the same time, we are now looking at some interesting healthtech project calls in early 2027, and I am looking for opportunities to use our Finnish innovation in Latvia as well. Latvian university hospitals have excellent doctors and a very high level of expertise. So, I have not forgotten Latvia, and I would also like to help raise awareness of digital innovation.